- Biological Sciences Department
- Office: D870
- Phone: (403) 332-4553
- Phone: (403) 332-4553
DegreesPh.D. (Biochemistry), University of Cambridge
MSc, Medical Biochemistry, University of Calgary
BSc, Biological Sciences, University of Lethbridge
ExpertiseCancer Research, Cell division, DNA damage, Pharmaceutical industry
Research AreasUnderstanding how cancer cells divide, Checkpoint adaptation
Previous Research AreasDrug discovery, Cancer research, Small molecules, Cell cycle, Cell motility
Office Hoursby appointment (e-mail) 8:00 AM to 5:30 PM
Biol 3105 Cell Signalling
Biol 3115 Cell Growth
BiographyPhD Biochemistry University of Cambridge
Senior Scientist in Cancer Drug Discovery
The Servier Pharmaceutical Company, Paris, France
Selected Publications1. Swift, L.H. and R.M. Golsteyn. "The relationship between checkpoint adaptation and mitotic catastrophe in genomic changes in cancer cells." In Genome Stability. Ed. Kovalchuk, I. and Kovalchuk, O. Elsevier, 2015.
2. Lewis, C.W., R.G. Taylor, and R.M. Golsteyn. "Measurement of Cdk1/cyclin B kinase activity by specific antibodies and western blotting." Methods in Molecular Biology. 1342:337-348. 2015.
3. Kernéis, S., L.H. Swift, C.W. Lewis, C. Bruyère, N. Oumata, P. Colas, S. Ruchaud, J. Bain and R.M. Golsteyn. "Natural product extracts of the Canadian prairie plant, Thermopsis rhombifolia, have anti-cancer activity in phenotypic cell based assays." Natural Product Research. 29:1026-1034. 2015.
4. Swift, L.H. and R.M. Golsteyn. "Genotoxic anti-cancer agents and their relationship to DNA damage, mitosis, and checkpoint adaptation in proliferating cancer cells." International Journal of Molecular Sciences 15:3403-3431. 2014.
5. Lewis, C.W., R.G. Taylor, P.M. Kubara, K. Marshall, L. Meijer, and R.M. Golsteyn. "A western blot assay to measure cyclin dependent kinase activity in cells or in vitro without the use of radioisotopes." FEBS Letters 587:3089-3095. 2013.
6. Kubara, P.M., S. Kernéis-Golsteyn, A. Studeny, B. Lanser, L. Meijer and R.M. Golsteyn. "Human cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents." Biochemical Journal, 446:373-381. 2012.
7. Perron-Sierra, F.M., N. Kucharkzyk, C. Boucley, C. Guyard-Daumas, S. Sciberras, C. Fouache, A. Studény, C. Bossard, P.J. Casara and R.M. Golsteyn. "Synthesis of cis-fused pyran indolocarbazole derivatives that inhibit FLT3 kinase and the DNA Damage Kinase, checkpoint kinase 1." Anti-Cancer Agents and Medicinal Chemistry 12:194-201. 2012.
8. Ferry, G., A. Studény, C. Bossard, P.M. Kubara, D. Zeyer, J.-P. Renaud, P. Casara, G. de Nanteuil, M. Wierzbicki, B. Pfeiffer, M. Prudhomme, S. Leonce, A. Pierré, J.A. Boutin, and R.M. Golsteyn. "Identification and characterization of novel Checkpoint kinase 1 inhibitors by in vitro and cell based screening." Life Sciences. 89:259-268. 2011.
9. Cahuzac, N., A. Studény, K. Marshall, I. Versteege, K. Wetenhall, B. Pfeiffer, S. Léonce, J.A. Hickman, A. Pierré, R.M. Golsteyn. "An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells." Cancer Letters. 289:178-187. 2010.
10. Tao, Y., C. Leteur, C. Yang, P. Zhang, M. Castedo, A. Pierré, R.M. Golsteyn, J. Bourhis, G. Kroemer, E. Deutsch. "Radiosensitization by Chir-124, a selective CHK1 inhibitor: Effects of p53 and cell cycle checkpoints." Cell Cycle. 8:1196-1205. 2009.
11. Anizon, F., R.M. Golsteyn, S. Léonce, B. Pfeiffer, M. Prudhomme. "A three-step synthesis from rebeccamycin of an efficient checkpoint kinase 1 inhibitor." European Journal of Medicinal Chemistry. 44: 2234-2238. 2009.
12. Parmentier J.-G., B. Portevin, R.M. Golsteyn, A. Pierré, J. Hickman, P. Gloanec, G. De Nanteuil. "Synthesis and CHK1 inhibitory potency of hymenialdisine analogues." Bioorganic & Medicinal Chemistry Letters. 19:841-844. 2009.
In The Media1. Leap -Alberta Cancer Foundation. "University of Lethbridge Bean Counters- Buffalo Bean" Fall 2015.
2. The Lethbridge Herald. "U of L research projects receive $200k in funding." 7 August 2015.
3. Western Producer (newspaper). "Cancer researcher plucking wild flowers." 2 July 2015
4. Summer 2015 (Country-guide.ca; Manitoba cooperator.ca; Grain News.ca) "Buffalo bean more than floral for cancer researchers." Lisa Guenther. 6 June 2015.
5. Radio "CJOC 94.7" and 98.1 FM. Pat Siedlecki. U of L researchers discover buffalo bean may have anti-cancer properties. 03 June 2015.
6. Radio "Country 95" FM. Patrick Burles. Southern Alberta plant could become cancer fighter according to U of L researchers. 02 June 2015.
7. QR77 Alberta News. "Out of this world technology to be transferred to the medical field". Peter Watts. Radio. 19 April 2013.
8. "The Tomorrow Cancer Project" Lethbridge College News. 12 February 2013.
Research InterestsThe Cancer Cell Laboratory focuses on two projects:
1. The Prairie to Pharmacy Project. We are investigating plant species from the prairie ecological zone for novel anti-cancer compounds. To date, we have identified 12 species with interesting properties. This is a multidisciplinary project that includes collaborators with international pharmaceutical companies.
2. Checkpoint Adaptation project. We examine how cancer cells respond to cancer treatments. We are testing the hypothesis that cancer cells escape a cytotoxic treatment by a pathway known as "checkpoint adaptation" (entering mitosis with damaged DNA). To test this, we use cultured human cells and cell biological techniques such as microscopy, RNA interference, transfection and Western blotting.
Interested students and recent PhD graduates are invited to apply for research positions.
Current Research and Creative Activity
|Title||Location||Grant Information||Principal Investigator||Co Researchers|
|A new direction in cancer research: Testing the role of epigenetics in failed cell division||Lethbridge, AB||
University of Lethbridge Research Fund, 2010-2011.
|An inverted light microscope to observe human cancer cells||Lethbridge, AB||
Alberta Cancer Foundation, 2010-2011.
|Associate Professor, Lethbridge, AB, Canada||Lethbridge, AB||Roy Golsteyn|
|Checkpoint adaptation: a molecular analysis of how human cells respond to genotoxic events||Lethbridge, AB||
Alberta Ingenuity/Innovation, 2010-2013.
|Title||Grant Agency||Completion Date|
|Characterization of Checkpoint adaptation in human cancer cells||Alberta Cancer Board 2008-2010||2010|
|Mitotic catastrophe in human cancer cells||University of Lethbridge Start-up funds 2007-2009||2009|
|Mitotic catastrophe, CNRS||French Embassy of Canada, 2008.||2008|
|Inhibitors of protein kinases||Institut de Recherches Servier||2007|
|Role of Cdc25C phosphorylation in DNA damage||CIFRE (Conventions Industrielles de Formation par la Recherche, France)||2007|